All cause mortaliteten var 10% (101 patienter) i gruppen behandlet med Aclasta sammenlignet med 13% (141 patienter) i placebogruppen.
All cause mortality was 10% (101 patients) in the Aclasta-treated group compared to 13% (141 patients) in the placebo group.